Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

as well as no use of rescue therapy during the 36-week study treatment period. The most common adverse events in the dupilumab group (occurring in at least three patients) included peripheral ...

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Rescue therapy could include treatment with high-potency topical ... More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and ...

BLA accepted for review Dupilumab (Regeneron and Sanofi ... sNDA accepted AVB-114 (Avobis Bio) Stem cell therapy Treatment of perianal fistulas in patients with Crohn disease.